BresaGen has offices and laboratories in Adelaide, Australia and Athens, Georgia USA and is represented by two divisions, Protein Pharmaceuticals and Cell Therapy.

    Operates a GMP facility with experience in the manufacture of recombinant proteins. The division has a pipeline of human therapeutic candidates in development and offers contract process development and manufacturing services.

    A research and development program that takes the company抯 proprietary position in embryonic stem cell differentiation and applies it to the treatment of neurodegenerative disease and gene based disorders. The division also has an extensive program developing catheter and imaging technology for neurosurgical cell delivery.